SCF and APC E3 Ubiquitin Ligases in Tumorigenesis

This title explores the physiological roles of Skp1-Cullin1-F-box Complex (SCF) and Anaphase Promoting Complex (APC) in normal cells and in tumor formation. It also discusses how SCF and APC may represent promising therapeutic targets to treat cancer.

This SpringerBrief explores the physiological roles of Skp1-Cullin1-F-box Complex (SCF) and Anaphase Promoting Complex (APC) in normal cells and in tumor formation. These two related, multi-subunit E3 ubiquitin ligase enzymes, APC and SCF are thought to be the major driving forces governing proper cell cycle progression. Defective cell cycle regulation leads to genomic instability and ultimately, cancer development. Selective degradation of key cell cycle regulators by the ubiquitin-proteasome system has been proven to be a major regulatory mechanism for ensuring ordered and coordinated cell cycle progression. The SCF and APC E3 ligases have been characterized to play pivotal roles in regulating the cell cycle progression by timely degrading various critical cell cycle regulators. This Brief reviews recent studies that have shown that deregulation of signaling pathways in which the two ubiquitin ligases are involved causes aberrant cell cycle regulation, in turn leading to tumorigenesis. The text also discusses how SCF and APC may present promising therapeutic targets to treat various cancers.

Includes updated profiles of SCF and APC cellular functions and their characterized ubiquitin substrates Introduces the emergent SCF family members in the human genome and summarizes phenotypes in which the adapter proteins of SCF and APC are manipulated to reflect the pathogenesis of human cancer Discusses how SCF and APC may represent promising therapeutic targets to treat various types of cancers Includes supplementary material: sn.pub/extras

Autorentext
Wenyi Wei, Ph.D, is Associate Professor of Pathology at Beth Israel Deaconess Medical Center, Harvard Medical School. Dr. Wei is an expert in the mE3 ubiquitin ligase complexes. He's on the editorial board of several journals including American Journal of Cancer Research, Molecular and Cellular Biology, Cancer Hallmarks, Cancer Research, and Journal of Biological Chemistry. He has published 47 scientific papers, which have received over 2,740 citations. Hiroyuki Inuzuka, Ph.D is Assistant Professor of Pathology at Beth Israel Deaconess Medical Center, Harvard Medical School.

Inhalt

1. Introduction.- 2. The Fbxw subclass of SCF E3 ubiquitin Ligases.- 3. The FbxL subclass of SCF E3 ubiquitin Ligases.- 4. The Fbxo subclass of SCF E3 ubiquitin Ligases.- 5. APC/Cdc20 and APC/Cdh1 E3 ubiquitin Ligases.- 6. Conclusions and Future Perspectives.